- Home
- DBRG vs HRMY Comparison
DBRG vs HRMY Comparison
Compare DBRG & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBRG | HRMY |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DBRG | HRMY |
|---|---|---|
| Price | $15.42 | $36.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $16.00 | ★ $49.75 |
| AVG Volume (30 Days) | ★ 4.6M | 612.6K |
| Earning Date | 02-20-2026 | 02-24-2026 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | N/A | ★ 50.44 |
| EPS | 0.06 | ★ 3.17 |
| Revenue | $100,346,000.00 | ★ $825,944,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | $189.77 | $16.28 |
| P/E Ratio | $252.58 | ★ $11.49 |
| Revenue Growth | N/A | ★ 21.13 |
| 52 Week Low | $6.41 | $25.52 |
| 52 Week High | $15.55 | $40.87 |
Technical Indicators
Market Signals| Indicator | DBRG | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 67.13 | 48.18 |
| Support Level | $15.32 | $36.27 |
| Resistance Level | $15.45 | $38.04 |
| Average True Range (ATR) | 0.07 | 1.18 |
| MACD | -0.10 | -0.03 |
| Stochastic Oscillator | 51.43 | 50.14 |
Price Performance
Historical ComparisonAbout DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.